Jacqueline Amato, MD
Psychiatry · Medford, ORNPI 1295707016
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,725 of the $26,611 with a category attached, or 62.8%. 22 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 53.3% of the total. Reporting peaked in 2021 at $10,767 and has fallen 83.6% since, to $1,771 in 2025. Among psychiatry clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 436 payments — averaging $61.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$14K
- AbbVie$5K
- Otsuka America Pharmaceutical, Inc.$3K
- Ironshore Pharmaceuticals Inc.$778
- Teva Pharmaceuticals USA, Inc.$691
- Axsome Therapeutics, Inc.$419
- plus $3K from 16 others
What the payments were for
- Consulting fees$2,3109%
- Speaking & faculty fees$16,72563%
- Food & beverage$7,43628%
- Education$1401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 70 | $14,183 |
| AbbVie(2 entities) | 66 | $5,448 |
| Otsuka America Pharmaceutical, Inc. | 56 | $2,505 |
| Ironshore Pharmaceuticals Inc. | 37 | $778 |
| Teva Pharmaceuticals USA, Inc. | 58 | $691 |
| Axsome Therapeutics, Inc. | 19 | $419 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $388 |
| Lundbeck LLC | 19 | $386 |
| Corium, LLC | 15 | $349 |
| Alkermes, Inc. | 18 | $336 |
| Vanda Pharmaceuticals Inc. | 12 | $235 |
| Neurocrine Biosciences, Inc. | 12 | $235 |
| Supernus Pharmaceuticals, Inc. | 7 | $170 |
| Eisai Inc. | 7 | $128 |
| E.r. Squibb & Sons, L.L.C. | 5 | $113 |
| Collegium Pharmaceutical, Inc. | 4 | $87 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Johnson & Johnson | 2 | $29 |
| Tempus AI, Inc | 1 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Novartis | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$13,125
- VRAYLAR$3,600
- ABILIFY MYCITE$1,485
- REXULTI$125
How this compares
$26,611 in reported general payments places this provider in the 95th percentile of 366 psychiatry providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 16 | $29,532 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 25 | $17,456 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $10,909 |
| Lisdexamfetamine Dimesylate | 26 | $5,020 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $2,587 |
| Trazodone Hcl | 40 | $1,640 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 33 | $1,621 |
| Duloxetine Hcl | 80 | $1,554 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 59 | $1,271 |
| Quetiapine Fumarate | 57 | $1,212 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $1,110 |
| Lorazepam | 84 | $737 |
| Lamotrigine | 66 | $716 |
| Bupropion XlBupropion Hcl | 39 | $697 |
| Escitalopram Oxalate | 50 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $14,183 | $29,53216 claims |
| Axsome Therapeutics, Inc.Auvelity | $419 | $10,90911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 366 psychiatry providers in Oregon.
Other psychiatry in Medford
- Joseph JackmovichMedford$973
- Andrew WilliamsBeaverton$84K
- Alisha MorelandPortland$20K
- Leigh Anne BresslerPortland$15K
- John LipkinEugene$15K
- Alfred LewyPortland$9K
- Hernan SchmidtEugene$8K
- Anca Maria BejenaruPortland$6K
- Erik VanderlipLake Oswego$6K
- Deric RavstenRoseburg$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.